A novel lipid-based oral drug delivery system of nevirapine

International Journal of PharmTech Research

Volumn 3, Issue 2, 2011, Pages 1159-1168

  Chudasama, Arpan ^a   Patel, Vineetkumar ^a   Nivsarkar, Manish ^a   Vasu, Kamala ^a   Shishoo, Chamanlal ^a  

^a B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

Author keywords

Anti HIV; Droplet size; Intestinal permeation; Nevirapine; Pseudoternary phase diagram; Self emulsifying drug delivery system

Indexed keywords

2 PYRROLIDINONE; CAPRYOL 90; CREMOPHOR; DIETHYLENE GLYCOL MONOETHYL ETHER; EMULSIFYING AGENT; GLYCEOL; LIPID; MACROGOL 400; NEVIRAPINE; OCTANOIC ACID; OCTANOIN; OLEIC ACID; POLYSORBATE 20; POLYSORBATE 80; PROPYLENE GLYCOL; SOLUPHOR P; SURFACTANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; EX VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; MALE; NONHUMAN; PH; PHOTON CORRELATION SPECTROSCOPY; RAT; SUSPENSION; TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84856258078     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Embretson J et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362: 359-362.
2. Pantaleo G et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-358.
3. Pantaleo G et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A 1991; 88: 9838-9842.
4. Fox CH et al. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis 1991; 164: 1051-1057.
5. Tenner-Racz K et al. Immunohistochemical, electron microscopic and in situ hybridization evidence for the involvement of lymphatics in the spread of HIV-1. Aids 1998; 2: 299-309.
6. Haase AT et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996; 274: 985-989.
7. Wishart DS et al. Drugbank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006; 34: D668-D672.
8. Pereira BG et al. Pseudopolymorphs and intrinsic dissolution of nevirapine. Cryst Growth Des 2007; 7: 2016-2023.
9. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm Res 1995; 12: 1561-1572.
10. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 1997; 25: 103-128.
11. Pouton CW. Formulation of self-emulsifying drug delivery systems. Adv Drug Deliv Rev 1997; 25: 47-58.
12. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying, and "self-microemulsifying" drug delivery systems. Eur J Pharm Sci 2000; 11 (2): S93-S98.
13. Pouton CW. Self-emulsifying drug delivery systems: assessment of the efficiency of emulsification. Int J Pharm 1985; 27: 335-348.
14. Wakerly MG et al. Evaluation of the self-emulsifying performance of a non-ionic surfactant-vegetable oil mixture. J Pharm Pharmacol 1987; 39: 6P.
15. Charman SA et al. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm Res 1992; 9: 87-93.
16. Shah NH et al. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994; 106: 15-23.
17. Gershanik T, Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 2000; 50: 179-188.
18. Mueller EA et al. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res 1994; 11: 151-155.
19. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV- 1 in patients receiving potent antiretroviral combination therapy. J Am Med Assoc 1998; 280: 67-71.
20. Chun TW et al. Relationship between preexisting viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active antiretroviral therapy. Nat Med 2000; 6: 757-761.
21. Dahan A, Hoffman A. Evaluation of chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci 2005; 24: 381-388.
22. Lin JH, et al. The effect of dosage from on oral absorption of L-365260, a potent CCKB receptor antagonist, in beagle dogs. Pharm Res 1991; 8: S-272.
23. Charman SA et al. Self-emulsifying drug delivery systems: formulation and biopharmaceutical evaluation of an investigational lipophilic compound. Pharm Res., 1992, 9: 87-93.
24. Hauss DA et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor, J Pharm Sci 1998; 87: 164-169.
25. Khoo SH et al. Formulation design and bioavailability assessment of lipidic selfemulsifying formulations of halofantrine. Int J Pharm 1998; 167: 155-164.
26. Porter CJH et al. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium chain lipid-based microemulsion formulation. Pharm Res 2004; 21: 1405-1412.
27. Bin F, Stewar JT. Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J Pharm Biomed Anal 2002; 28: 903-908.
28. Anbazhagan S et al. Simultaneous quantification of stavudine, lamivudine and nevirapine by UV spectroscopy, reverse phase HPLC and HPTLC in tablets. J Pharm Biomed Anal 2005; 39: 801-804.
29. Djordjevic L et al. Characterization of caprylocaproyl macrogolglycerides basedmicroemulsion drug delivery vehicles for an amphiphilic drug. Int J Pharm 2004; 271: 11-19.
30. Sarkar M et al. Development and validation of RP-HPLC and ultraviolet spectrophotometric methods of analysis for the quantitative estimation of antiretroviral drugs in pharmaceutical dosage forms. J Chromato B 2006; 830: 349-354.
31. United States Pharmacopoeia, 30/NF25. U S Pharmacopoeial Convention, Rockville, MD 2007; 1: 810.
32. Subramanian N et al. Formulation design of self-microemulsifying drug delivery systems for improved oral bioavailability of celecoxib. Biol Pharm Bull 2004; 27: 1993-1999.
33. Cirri M et al. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems. Int J Pharm 2007; 340: 84-91.
34. Zhang P et al. Preparation and evaluation of self-emulsifying drug delivery system of oridonin. Int J Pharm 2008; 355: 269-276.
35. United States Pharmacopoeia, 30/NF25. U S Pharmacopoeial Convention, Rockville, MD 2007; 1: 807.
36. Kabra V et al. Simulataneous quantitative determination of zidovudine and nevirapine in human plasma using isocratic, reverse phase high performance liquid chromatography. Trop J Pharm Res 2009; 8(1): 79-86.
37. Mandloi DK et al. Method development and validation of RP-HPLC method in the detection of nevirapine in bulk drug and tablet formlation and application in in vitro dissolution study. J Global Pharm Tech 2009; 1(1): 54-61.
38. Klous MG et al. Process characterisation, optimisation and validation of production of diacetylmorphine/caffeine sachets: a design of experiments approach. Int J Pharm 2004; 285: 65-75.
39. Kommura TR et al. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm 2001; 212: 233-246.
40. Kang BK et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004; 274: 65-73.
41. Itoh K et al. Improvement of physicochemical properties of N-4472 part I formulation design by using self-microemulsifying system. Int J Pharm 2002; 238: 153-160.
42. Smith P. Methods for evaluating intestinal permeability and metabolism in vitro. Pharm Biotech 1996; 8: 13-34.
43. Franceschinis E et al. Self-emulsifying pellets prepared by wet granulation in high-shear mixer: influence of formulation variables and preliminary study on the in vitro absorption. Int J Pharm 2005; 291: 87-97.
44. Yao J et al. Preparation of nobiletin in self-microemulsifying systems and its intestinal permeability in rats. J Pharm Pharmaceut Sci 2008; 11(3): 22-29.
45. Chen Y et al. Self-microemulsifying drug delivery system (SMEDDS) of vinpoetine: formulation development and in vivo assessment. Bio Pharm Bull 2008; 31(1): 118-125.
46. Wu W et al. Enhanced bioavailability of silymarin by selfmicroemulsifying drug delivery system. Eur J Pharm Biopharm 2006; 63: 288-294.
47. Shah XY et al. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells. Eur J Pharm Sci 2005; 24: 477-486.
48. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004; 58: 173-182.